E	_&	 
FORM PTO-1449 (Rev. 2-32) P		

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.	SERIAL NO.
1188-37 RCE/DIV	10/728,015
APPLICANT Minotti et al.	CONFIRMATION NO.
FILING DATE	GROUP
December 4, 2003	1623

## **U.S. PATENT DOCUMENTS**

	<del></del>	0.5.1	WITHI DOCOMENT	<u> </u>		
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
M	4,203,900	05/20/90	Kaiser		_	
	4,206,221	06/03/90	Miller et al.	·		•
	4,303,439	12/01/81	Howe et al.			
	4,354,029	10/12/82	Kaiser et al.		<u> </u>	
	4,360,678	11/23/82	Howe et al.	_	~	•
· ·	4,443,611	04/17/84	Kaiser		_	
	4,543,414	09/24/85	Carson			
-	4,743,700	05/10/88	Jamm et al.			•
	4,814,470	03/21/89	Colin et al.		_	
•	4,857,653	08/15/89	Colin et al.			
	4,876,399	10/24/89	Holton et al.			
	4,877,881	10/31/89	Belliotti et al.			
	4,924,002	05/08/90	Kostlan		_	
	4,924,011	05/08/90	Denis et al.		5	
	4,924,012	05/08/90	Colin et al.		_	
an .	4,942,184	07/17/90	Haugwitz et al.			

**EXAMINER** 

dehone

DATE CONSIDERED

9/16/04

(Rev. 2-32)	449 U.S. DEPARTM PATENT AND TRAC				CKET NO. RCE/DIV		RIAL NO. /728,015
IPE W	INFORMATION D			APPLICAI Minotti el		cc	ONFIRMATION NO.
UR 0 8 2004	(Use several sheets	if necessary)		FILING D	ATE r 4, 2003		OUP 23
BANEMARY OF				-	1	<u> </u>	
BANEMAN.	4,960,790	10/02/90	Stella et al.	····	· ·		
	5,015,744	05/14/91	Hotan		ļ		
_	5,059,699	10/22/91	Kingston et	al.		· <u> </u>	
	5,128,478	07/07/92	Ito et al.				
,	5,136,060	08/04/92	Holtan				
	5,194,635.	03/16/93	Kingston et	al.	_	_	
	5,208,237	05/04/93	Hewawasam	et al.			
	5,227,400	07/13/93	Hoiton et al.			. <b>-</b> -	
	5,243,045	09/07/93	Holton et al.	···	<del></del> -		
	5,254,580	10/19/93	Chen			_	
	5,264,591	11/23/93	Bombardelli	et al.		_	
	5,272,171	12/21/93	Ueda et al.	<del></del>	<u> </u>	_	
	5,278,324	01/11/94	Kingston et a	ıl.		_	
	5,283,253	02/01/94	Holton et al.			_	
	5,296,506	03/22/94	Kingston ·		<u> </u>		
	5,319,112	06/07/94	Kingston et.	al.			
	5,352,806	10/04/94	Gunawardan	et al.			
m	5,399,726	03/21/95	Holton et al.				

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE SERIAL NO. ATTY. DOCKET NO. (Rev. 2-32) PATENT AND TRADEMARK OFFICE 1188-37 RCE/DIV 10/728,015 INFORMATION DISCLOSURE APPLICANT CONFIRMATION NO. STATEMENT BY APPLICANT Minotti et al. FILING DATE **GROUP** (Use several sheets if necessary) December 4, 2003 1623 THADEN! 5,420,337 05/30/95 Patel et al. 5,440,056 08/08/95 Klein et al. 5,449,790 09/12/95 Zheng et al. 5,468,769 11/21/95 -Klein et al. 5,476,954 12/19/95 Borzat et al. 5,556,878 09/17/96 Kelly et al. 5,580,997 Bouchard et al. 12/02/96 5,589,502 12/31/96 Tsujihara et al. 5,616,739 04/01/97 Mas et al. 5,618,952 04/08/97 Holton et al. 5,621,121 04/15/97 Cammercon et al. 5,635,531 06/03/97 Chen 5,637,732 06/10/97 Holton et al. 5,646,176 07/08/97 Golik et al. 5,670,658 09/23/97 **Bastart** 5,677,470 10/14/97 Tsujihara et al. 5,710,287 01/20/98 Holton et al. m 5,721,268 02/24/98 Holton et al. Mehane **EXAMINER DATE CONSIDERED** 

FORM PTO- (Rev. 2-32)	1449 U.S. DEPARTM PATENT AND TRA			ATTY. DO 1188-37 F			AL NO. 28,015
Cio	INFORMATION D STATEMENT BY	ISCLOSURE APPLICANT		APPLICAN Minotti et		CON	FIRMATION NO
O S TOL THE	(Use several sheet	s if necessary)		FILING DA December		GRO 1623	
TRADELL	5,728,687	03/17/98	Bissery		_		
	5,728,725	03/17/98	Holton et al	•		<u>~</u>	
	5,760,252	06/02/98	Holton et al	•	_		
	5,767,296	06/16/98	Terasawa e	t al.	_		
	5,773,461	06/30/98	Wittma et a	l		_	
	5,808,102	09/15/98	Poss et al.	<del></del>			
	5,840,931	11/24/98	Bouchard et	al.	. —		
	5,847,170	12/08/98	Bouchard et	al.			
	5,889,043	03/30/99	Bouchard et	al.	_		
	5,908,835	06/01/99	Bissery				
_	6,005,120	12/21/99	Holton et al.				
	6,020,507	02/01/00	Gibson			_	
	6,043,375	03/28/00	Borzat et al.		_		
	6,072,060	06/06/00	Suidell et al.		_		
	6,096,909	08/01/00	Ojima		-		
	6,100,411	08/08/00	Ojima		_		
	6,214,863	04/10/01	Bissery				_
gh	6,239,167	05/29/01	Bissery		-		

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.

**DATE CONSIDERED** 

duhan

**EXAMINER** 

9/16/04

FORM PTO-PEREN 2-32) MAR 0 8 2004

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE REPORT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.	SERIAL NO.
1188-37 RCE/DIV	10/728,015
APPLICANT Minotti et al.	CONFIRMATION NO.
FILING DATE	GROUP
December 4, 2003	1623

M	6,248,908	06/01	Kant	-	_	
	6,340,701	01/02	Charl et al.		(	
au	6,353,120	03/02	Kant			

FOREIGN PATENT DOCUMENTS

	10	ICLIONIA	LIVI DOCUME	4110			
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB	TRANS	LATION
INITIAL	NUMBER		*		CLASS	YES	NO
· an	JP 55-145650	11/13/80	Japan		)		
	JP 61-005022	01/10/86	Japan				
	JP 61-51578	11/10/86	Japan				
	JP 60-222416	11/07/85	Japan		_		
	JP61-115022	06/02/86	Japan		_		
	JP 9208572A	08/12/97	Japan		-		
	WO 90/02738	03/22/90	PCT		}		
	WO 92/09589	06/11/92	PCT		)		
	WO 92/19765	11/12/92	. PCT		•		
	WO 94/07876	04/14/94	PCT				
	WO 94/13655	06/23/94	PCT	_	_		
W	WO 94/14787	07/07/94	PCT				

EX	٨	M	N	CD
IT. A	м	IVI	IV	r.K

duhan

DATE CONSIDERED

9/16/04

FORM PTO-1449 U
PE (Rev. 2-32) PATE
INFO
STA

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Rev. 2-32) PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use several sheets if necessary)

APPLICANT CONFIRMATION NO.	ATTY. DOCKET NO. 1188-37 RCE/DIV	SERIAL NO. 10/728,015
Minotti et al.	APPLICANT Minotti et al.	CONFIRMATION NO.

FILING DATE GROUP December 4, 2003 1623

WO 95/03265	02/02/95	PCT				
WO 96/00724	01/11/96	РСТ	_	_		
WO 96/13495	05/09/96	РСТ	_	_		
WO 96/14309	05/17/96	PCT	-	_		
WO 96/23779	08/08/96	PCT	_			
WO 97/09979	03/20/97	PCT		_		
WO 97/23472	07/03/97	PCT		<u> </u>		
WO 97/32578	09/12/97	PCT				
WO 97/32869	09/12/97	PCT		-		
WO 98/01435	01/15/98	PCT				
WO 98/22451	05/28/98	PCT		(		
WO 99/33462	07/08/99	PCT		-		
EP 0 359 516 B1	08/10/94	EPO	<b>-</b>	1		
EP 0 400 971 B1 & A3	07/29/98	EPO		_		
EP 0 428 376 B1	01/10/96	EPO				
EP 0 505 047 B1 & A1	04/24/96	EPO				
EP 0 537 905 B1 & A1	03/06/96	EPO			`	
EP 0 604 910 A1	07/06/04	EPO	_	·		
	WO 96/00724  WO 96/13495  WO 96/13495  WO 96/13499  WO 96/23779  WO 97/09979  WO 97/23472  WO 97/32578  WO 97/32869  WO 98/01435  WO 98/22451  WO 99/33462  EP 0 359 516 B1  EP 0 400 971 B1 & A3  EP 0 428 376 B1  EP 0 505 047 B1 & A1  EP 0 537 905 B1 & A1	WO 96/00724 01/11/96 WO 96/13495 05/09/96 WO 96/13495 05/17/96 WO 96/14309 05/17/96 WO 96/23779 08/08/96 WO 97/09979 03/20/97 WO 97/23472 07/03/97 WO 97/32578 09/12/97 WO 97/32869 09/12/97 WO 98/01435 01/15/98 WO 98/22451 05/28/98 WO 99/33462 07/08/99 EP 0 359 516 B1 08/10/94 EP 0 400 971 B1 & A3 07/29/98 EP 0 428 376 B1 01/10/96 EP 0 505 047 B1 & A1 04/24/96 EP 0 537 905 B1 & A1 03/06/96	WO 96/00724       01/11/96       PCT         WO 96/13495       05/09/96       PCT         WO 96/14309       05/17/96       PCT         WO 96/23779       08/08/96       PCT         WO 97/09979       03/20/97       PCT         WO 97/23472       07/03/97       PCT         WO 97/32578       09/12/97       PCT         WO 97/32869       09/12/97       PCT         WO 98/01435       01/15/98       PCT         WO 98/22451       05/28/98       PCT         WO 99/33462       07/08/99       PCT         EP 0 359 516 B1       08/10/94       EPO         EP 0 400 971 B1       & A3       07/29/98       EPO         EP 0 428 376 B1       01/10/96       EPO       EPO         EP 0 557 905 B1       & A1       04/24/96       EPO         EP 0 537 905 B1       & A1       03/06/96       EPO	WO 96/00724       01/11/96       PCT         WO 96/13495       05/09/96       PCT         WO 96/14309       05/17/96       PCT         WO 96/23779       08/08/96       PCT         WO 97/09979       03/20/97       PCT         WO 97/23472       07/03/97       PCT         WO 97/32578       09/12/97       PCT         WO 97/32869       09/12/97       PCT         WO 98/01435       01/15/98       PCT         WO 98/22451       05/28/98       PCT         WO 99/33462       07/08/99       PCT         EP 0 359 516 B1       08/10/94       EPO         EP 0 400 971 B1       8 A3       07/29/98       EPO         EP 0 428 376 B1       01/10/96       EPO       —         EP 0 505 047 B1       8 A1       04/24/96       EPO       —         EP 0 537 905 B1       8 A1       03/06/96       EPO       —	WO 96/00724       01/11/96       PCT       —         WO 96/13495       05/09/96       PCT       —         WO 96/14309       05/17/96       PCT       —         WO 96/23779       08/08/96       PCT       —         WO 97/09979       03/20/97       PCT       —         WO 97/23472       07/03/97       PCT       —         WO 97/32578       09/12/97       PCT       —         WO 97/32869       09/12/97       PCT       —         WO 98/01435       01/15/98       PCT       —         WO 98/22451       05/28/98       PCT       —         WO 99/33462       07/08/99       PCT       —         EP 0 359 516 B1       08/10/94       EPO       —         EP 0 400 971 B1       &A3       07/29/98       EPO       —         EP 0 537 905 B1       &A1       04/24/96       EPO       —         EP 0 537 905 B1       &A1       03/06/96       EPO       —	WO 96/00724       01/11/96       PCT       —         WO 96/13495       05/09/96       PCT       —         WO 96/13495       05/17/96       PCT       —         WO 96/23779       08/08/96       PCT       —         WO 97/09979       03/20/97       PCT       —         WO 97/23472       07/03/97       PCT       —         WO 97/32578       09/12/97       PCT       —         WO 97/32869       09/12/97       PCT       —         WO 98/01435       01/15/98       PCT       —         WO 98/22451       05/28/98       PCT       —         WO 99/33462       07/08/99       PCT       —         EP 0 359 516 B1       08/10/94       EPO       —         EP 0 428 376 B1       01/10/96       EPO       —         EP 0 505 047 B1       &A1       04/24/96       EPO       —         EP 0 537 905 B1       &A1       03/06/96       EPO       —

**EXAMINER** 

dishare

DATE CONSIDERED

a/16/04

FORM PTO-1	449 U.S. DEPARTMENT PATENT AND TRADEM	OF COMMERCE ARK OFFICE			DOCKET NO 37 RCE/DIV		SERIAL N 10/728,0	
0 8 2004	INFORMATION DISC STATEMENT BY APP			APPLIC Minotti			CONFIRM	ATION NO
EMARY OF	(Use several sheets if r	ecessary) .		FILING Decem	DATE ber 4, 200	3	GROUP 1623	
14	1,061,330	08/28/79	Canada		-			
	1,695,918	05/06/71	German			_		
cu	2,919,891	12/04/80	German		_			
							_	
							`	
	Oxford, ( ECCO: T Doctor's www.psl DG Disp Advanced retrieved	liver function; Great Britain; Caxol/doxorubi Guide, 'Online group.com/dg/ atch - ECCO: It Breast Cance from the Intern	cin Impro e!, 22 Sep 13144a.h New Drug er, Doctor net: www	o. 1; Jar oves Sur otember tm; retr g Comb c's Guid v.pslgro	rvival in N 1999; ret ieved 200 ination Ende; 'Online oup.com/d	Metasta rieved 2-11-0 nhances el; 19 S g/12c4	ntic Breast from the 1 6. s Treatme September 52.htm.	Cancer; Internet: nt for 1999;
	——pharmaco 1999), pa	"Doxorubicin/ kinetics." Sem ges 14-19,	ninars in (	Oncolog	gy, Vol. 20	6, No. 3	3, Suppl. 9	9 (June
	the intera	al., "Human pletion between Journal of clin	doxorubi	cin and	paclitaxel	patien	ts with br	east
one	doxorubio do	"In vitro active in and cisplati	n on prin	ary cell	l cultures	of hum	an breast	h cancers.'
		ncer Research	and Trea	tment, 3	<u> 54, 1995, j</u>	pages o	<u>13-39</u> .	

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Rev. 2-32) PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 1188-37 RCE/DIV	SERIAL NO. 10/728,015
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT Minotti et al.	CONFIRMATION NO.
MAR O 8 2004 W	Use several sheets if necessary)	FILING DATE December 4, 2003	GROUP 1623
Wahl et al. "Selective tumor sensitization to taxancs with the mab-drug conjugate CBR96-doxorubicin." Abstract: Int. J. Cancer vol. 4 (15 Aug. 2001), pages 590-600.			_

**EXAMINER** 

duhan

DATE CONSIDERED

9/16/04